Metastatic
-
RYBREVANT® (amivantamab-vmjw) Demonstrates Promising and Durable Long-Term Responses in Difficult-to-Treat Colorectal Cancer
Johnson & Johnson’s amivantamab combined with chemotherapy shows promising results in metastatic colorectal cancer. The bispecific antibody, targeting EGFR and MET, achieved a 51% overall response rate in RAS/BRAF wild-type patients. Longer-term data indicate sustained efficacy, with over 70% response in the first-line setting and durable responses exceeding two years. The combination also demonstrated activity in patients with liver metastases, with a 57% ORR. The safety profile was consistent with prior studies, with low discontinuation rates.
